Drug intelligence / Profile preview

propofol + rocuronium + fentanyl

Development stage
Unknown
Lead developer
AkzoNobel
Modality
Small Molecules
Administration
Intravenous
01

Overview

This is a combination of three intravenous drugs—propofol, rocuronium, and fentanyl—commonly used together for the induction of general anesthesia. Propofol is a sedative-hypnotic agent that induces loss of consciousness by potentiating gamma-aminobutyric acid (GABA) activity at GABA-A receptors. Rocuronium is a non-depolarizing neuromuscular blocking agent that facilitates muscle relaxation and endotracheal intubation by competitively inhibiting acetylcholine at nicotinic receptors on the motor endplate. Fentanyl is a potent synthetic opioid analgesic that acts primarily as an agonist at mu-opioid receptors to provide analgesia and blunt sympathetic responses to airway manipulation. This drug combination provides rapid onset of unconsciousness, muscle relaxation for intubation, and pain control during surgical procedures[2][3][6].

Other names
propofol + rocuronium + fentanyl-Memorial Sloan Kettering Cancer CenterPropofol+ Rocuronium+ Fentanyl + Inhalational
02

Targets

GABRB3 (GABA-A receptor subunit beta-3)Nicotinic Acetylcholine ReceptorMOR (Mu opioid receptor)

Beyond the preview

Go deeper on propofol + rocuronium + fentanyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + rocuronium + fentanyl.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call